Welcome to our dedicated page for Zivo Bioscience SEC filings (Ticker: ZIVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ZIVO Bioscience filings document a biotech and agtech research and development company with common stock and warrants and an intellectual property portfolio covering proprietary algal and bacterial strains, biologically active molecules and complexes, cultivation techniques, production techniques, and patented or patent-pending inventions for human and animal health.
Recent Form 8-K disclosures address corporate-status matters involving SEC reporting obligations and OTC market securities, Board determinations, executive finance leadership changes, separation agreements, compensatory arrangements, and other material events tied to ZIVO's public-company governance and capital structure.
Zivo Bioscience, Inc. (ZIVO) director and 10% owner Christopher D. Maggiore was granted 1,075 nonstatutory stock options on 10/02/2025 under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $10,964.38. The options have an exercise price of $12.03, are exercisable immediately on 10/02/2025, and expire on 10/02/2035. The filing shows the underlying common stock amount as 1,075 shares and reports the transaction on a Form 4 signed 10/06/2025. This is a routine director compensation award recorded as equity rather than cash.
Zivo Bioscience, Inc. (ZIVO) director Alison Cornell received a grant of 1,223 nonstatutory stock options on 10/02/2025 under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees totaling $12,476.71. The options have an exercise price of $12.03, are exercisable immediately on 10/02/2025, and expire on 10/02/2035
This transaction increases the reporting person’s direct beneficial ownership by 1,223 underlying shares. The filing is a routine director compensation disclosure showing equity issued instead of cash fees to align compensation with shareholder interests.
Laith Yaldoo, a director and 10% owner of Zivo Bioscience, Inc. (ZIVO), reported a purchase of 15,322 shares of the company's common stock on 09/30/2025 at a price of $15.99 per share. After the transaction, the filing shows beneficial ownership of 573,436 shares held indirectly through HEP Investments LLC. The Form 4 was signed on 10/02/2025.
This report documents an insider acquisition, increasing the reporting person's indirect stake via an investment vehicle. The filing does not disclose any derivative transactions or additional context for the purchase beyond the amounts, price, and ownership form.